Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: Effectiveness in clinical practice

Addiction

Volumn 108, Issue 12, 2013, Pages 2193-2201

  Stapleton, John ^a,b   West, Robert ^b   Hajek, Peter ^c   Wheeler, Jenny ^d   Vangeli, Eleni ^b   Abdi, Zeinab ^a   O'Gara, Colin ^e   Mcrobbie, Hayden ^c   Humphrey, Kirsty ^c   Ali, Rachel ^f   Strang, John ^a,g   Sutherland, Gay ^a,g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Mid Essex PCT   (United Kingdom)

^e St John of God Hospitaller Services Ireland   (Ireland)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bupropion; Combination treatment; Depression; NHS; NRT; Randomized trial; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; NICOTINE GUM; VARENICLINE;

ADULT; ARTICLE; BEHAVIOR THERAPY; COMBINATION TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NHS; NRT; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED TRIAL; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; CLINICAL TRIAL; PREVENTION AND CONTROL; PROCEDURES;

BUPROPION; COMBINATION TREATMENT; DEPRESSION; NHS; NRT; RANDOMIZED TRIAL; SMOKING CESSATION; VARENICLINE;

ADULT; BEHAVIOR THERAPY; BUPROPION; COMBINED MODALITY THERAPY; DOPAMINE UPTAKE INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84887605939     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.12304     Document Type: Article

References (23)

1. Jorenby D. E., Leischow S. J., Nides M. A., Rennard S. I., Johnston J. A., Hughes A. R. etal. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 685-691.
2. Górecka D., Bednarek M., Nowiński A., Puścińska E., Goljan-Geremek A., Zieliński J. Effect of treatment for nicotine dependence in patients with COPD. Pneumonol Alergol Pol 2003; 71: 411-417.
3. Uyar M., Filiz A., Bayram N., Elbek O., Herken H., Topcu A. etal. A randomized trial of smoking cessation. Medication versus motivation. Saudi Med J 2007; 28: 922-926.
4. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2010; (1): CD000031.
5. Evins A. E., Cather C., Culhane M. A., Birnbaum A., Horowitz J., Hsieh E. etal. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27: 380-386.
6. George T. P., Vessicchio J. C., Sacco K. A., Weinberger A. H., Dudas M. M., Allen T. M. etal. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008; 63: 1092-1096.
7. Grant K. M., Kelley S. S., Smith L. M., Agrawal S., Agrawal S., Meyer J. R., Romberger D. J. Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol 2007; 41: 381-391.
8. Killen J. D., Robinson T. N., Ammerman S., Hayward C., Rogers J., Stone C. etal. Randomized clinical trial of the efficacy of bupropion combined with nicotine patch in the treatment of adolescent smokers. J Consult Clin Psychol 2004; 72: 729-735.
9. Simon J. A., Duncan C., Carmody T. P., Hudes E. S. Bupropion plus nicotine replacement no better than replacement alone. J Fam Pract 2004; 53: 953-954.
10. Hajek P., Belcher M., Stapleton J. A. Enhancing the impact of groups: an evaluation of two group formats for smokers. Br J Clin Psychol 1985; 24: 289-294.
11. Hajek P. Withdrawal-oriented therapy for smokers. Addiction 1989; 84: 591-598.
12. National Institute for Health and Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. Technology Appraisal Guidance no. 39. London: National Institute for Health and Clinical Excellence; 2002.
13. Kozlowski L. T., Porter C. Q., Orleans C. T., Pope M. A., Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HSI. Drug Alcohol Depend 1994; 34: 211-216.
14. West R., Hajek P., Stead L., Stapleton J. A. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303.
15. Foulds J., Stapleton J., Hayward M., Russell M. A., Feyerabend C., Fleming T., Costello J. Transdermal nicotine patches with low-intensity support in outpatients in a general hospital. Arch Fam Med 1993; 2: 417-427.
16. Moher D., Schulz K. F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285: 1987-1991.
17. Stead L. F., Perera R., Bullen C., Mant D., Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (3): CD000146.
18. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2010; (12): CD006103.
19. Hurt R. D., Sachs D. P., Glover E. D., Offord K. P., Johnston J. A., Dale L. C. etal. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195-1202.
20. Hayford K. E., Patten C. A., Rummans T. A., Schroeder D. R., Offord K. P., Croghan I. T. etal. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999; 174: 173-178.
21. Cox L. S., Patten C. A., Niaura R. S., Decker P. A., Rigotti N., Sachs D. P. etal. Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression. J Gen Intern Med 2004; 19: 828-834.
22. Brown R. A., Niaura R., Lloyd-Richardson E. E., Strong D. R., Kahler C. W., Abrantes A. M. etal. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. Nicotine Tob Res 2007; 9: 721-730.
23. Gunnell D., Irvine D., Wise L., Davies C., Martin R. M. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805.